HOMG
MCID: PRM237
MIFTS: 43

Primary Hypomagnesemia (HOMG)

Categories: Gastrointestinal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Primary Hypomagnesemia

MalaCards integrated aliases for Primary Hypomagnesemia:

Name: Primary Hypomagnesemia 12 29 6 15 71
Familial Primary Hypomagnesemia 52 71
Genetic Primary Hypomagnesemia 52 58
Primary Familial Hypomagnesemia 12
Hypomagnesemia 1, Intestinal 71
Homg 12

Characteristics:

Orphanet epidemiological data:

58
genetic primary hypomagnesemia
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Adolescent,Adult,Childhood; Age of death: any age;

Classifications:

Orphanet: 58  
Rare renal diseases
Inborn errors of metabolism


External Ids:

Disease Ontology 12 DOID:0060879
ICD10 32 E83.4
ICD10 via Orphanet 33 E83.4
Orphanet 58 ORPHA34526
UMLS 71 C0268448 C1865974 C4049202

Summaries for Primary Hypomagnesemia

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 34526 Definition A rare mineral absorption and transport disorder characterized by a selective defect in renal or intestinal magnesium (Mg) absorption, resulting in a low Mg concentration in the blood. Epidemiology To date, more than 500 cases of Familial primary hypomagnesemia (FPH) have been described in the literature. Clinical description Clinical manifestations include weakness, fatigue, increased neuromuscular excitability (muscle fasciculation, cramps, tremor carpopedal spasms, numbness in the hands and tetany), central nervous system manifestations (lethargy, drowsiness, depression, agitation and generalized seizures ), and cardiac manifestations (atrial or ventricular tachycardia, and premature contractions). Chronic hypomagnesemia may be associated with chondrocalcinosis. Hypomagnesemia is frequently accompanied by hypocalcemia and sometimes by hypokalemia. Depending on the renal segment involved, FPH can be associated with hypercalcuria (when the defect of magnesium reabsorption is in the thick ascending limb of Henle's loop) or with hypocalcuria or normocalcuria (when the defect of magnesium reabsorption is in distal convoluted tubule). The severity of the clinical manifestations and the age of onset is variable (depends on the implicated transporter and type of inheritance. Severe and early presentation is observed in primary hypomagnesemia with secondary hypocalcemia (PHSH, recessive inheritance; see this term), while the mild phenotype is observed in older children and adults in dominant diseases. Other hereditary renal diseases are frequently associated with hypomagnesemia such as salt losing tubulopathies: classic Bartter syndrome , Gitelman syndrome, EAST syndrome, renal cysts and diabetes syndrome and autosomal dominant hypocalcemia (see these terms). Etiology Renal reabsorption of Mg occurs in the loop of Henle via a passive paracellular transport process implicating claudin-16 and claudin-19 while in the intestine and in the distal convoluted tubule (DCT), reabsorption is achieved by an active process mediated by TRPM6. FPH is caused by mutations in genes encoding key proteins with direct or indirect involvement in active Mg handling, such as CLDN16 , CLDN19 , CNNM2 , EGF , FXYD2 , KCNA1 , HNF1B and TRPM6 . Diagnostic methods Clinically, Chvostek's (twitching of facial muscles in response to tapping over the area of the facial nerve) and Trousseau's (carpopedal spasm resulting from ischemia) signs can detect hypomagnesemia in a specific and sensitive manner. Diagnosis is also established by simultaneous evaluation of serum Mg and urinary Mg excretion. Presence of hypomagnesemia with adapted urinary Mg excretion (<1mmol/24h or fractional excretion (FE) < 1%) indicates an extra renal origin. Elevated fecal Mg levels indicate an intestinal defect. In contrast, hypomagnesemia with increased urinary Mg excretion (> 2 mmol/24h or FE >2%) indicates a renal origin. In mixed intestinal and renal hypomagnesemia (PHSH), the renal reabsorption defect is only observed after an intravenous magnesium load test. Diagnosis is confirmed by molecular screening of genes involved in FPH. Differential diagnosis Differential diagnosis includes isolated Mg malabsorption, hypoparathyroidism and drug toxicity (diuretics, aminoglycosides, proton pump inhibitors, pentamidin, EGF receptor antagonists, calcineurin inhibitors and platin salts). Genetic counseling Transmission is autosomal recessive or autosomal dominant. Management and treatment Treatment of FPH involves substitution with oral Mg. In cases of intolerance, patients may be treated with intramuscular Mg sulfate. Treatment and doses should be adjusted according to gastrointestinal tolerance and clinical manifestations. Intravenous Mg and calcium therapies may be given during symptomatic attacks. Prognosis Prognosis is highly dependent on the rapidity of diagnosis and treatment. Complications or death resulting from untreated convulsions or tetany may be observed in certain forms of FPH. Visit the Orphanet disease page for more resources.

MalaCards based summary : Primary Hypomagnesemia, also known as familial primary hypomagnesemia, is related to hypomagnesemia 2, renal and hypomagnesemia 3, renal, and has symptoms including seizures, polydipsia and abdominal pain. An important gene associated with Primary Hypomagnesemia is CLDN16 (Claudin 16), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Ion channel transport. The drugs Magnesium Sulfate and Anesthetics have been mentioned in the context of this disorder. Affiliated tissues include testes and brain.

Disease Ontology : 12 A metal metabolism disorder characterized by very low serum magnesium levels often with secondary hypocalcemia with onset typically in the first months of life.

Related Diseases for Primary Hypomagnesemia

Diseases related to Primary Hypomagnesemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 hypomagnesemia 2, renal 33.6 FXYD2 CLDN16
2 hypomagnesemia 3, renal 32.7 TRPM6 FXYD2 CLDN16 AP1M1
3 hypomagnesemia 1, intestinal 32.5 TRPM7 TRPM6 PTH CLDN19 CLDN16
4 hypomagnesemia 5, renal, with or without ocular involvement 31.1 TALDO1 SLC12A1 KCNJ1 CLDN19 CLDN16
5 hypocalcemia, autosomal dominant 1 29.6 TRPM6 PTH KCNJ1 CLDN16
6 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 12.6
7 genetic primary hypomagnesemia with normocalciuria 12.3
8 genetic primary hypomagnesemia with hypocalciuria 12.3
9 primary hypomagnesemia with refractory seizures and intellectual disability 12.3
10 familial primary hypomagnesemia with normocalciuria and normocalcemia 12.3
11 hypomagnesemia 4, renal 10.3 TRPM6 FXYD2
12 deafness, autosomal recessive 29 10.3 CLDN19 CLDN16
13 hypercalciuria, absorptive, 2 10.2 KCNJ1 CLDN16
14 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection, and neoplasia 10.2 TRPM7 TRPM6
15 nephrolithiasis, uric acid 10.2 CLDN19 CLDN16
16 bartter syndrome, type 2, antenatal 10.1 SLC12A1 KCNJ1
17 hypoparathyroidism 10.1
18 antenatal bartter syndrome 10.1 SLC12A1 KCNJ1
19 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.0 TRPM6 SLC12A1 KCNJ1
20 atrial standstill 1 10.0
21 diarrhea 10.0
22 renal tubular transport disease 10.0 SLC12A1 PTH KCNJ1
23 mineral metabolism disease 10.0 SLC12A1 PTH KCNJ1
24 dent disease 1 9.9 SLC12A1 KCNJ1
25 bartter syndrome, type 1, antenatal 9.9 SLC12A1 KCNJ1 CLDN19 CLDN16
26 hyperphosphatemia 9.8
27 autosomal recessive disease 9.8
28 rickets 9.8
29 dilated cardiomyopathy 9.8
30 distal arthrogryposis 9.8 SLC12A1 PTH KCNJ1
31 arthrogryposis, distal, type 3 9.7 SLC12A1 KCNJ1
32 bartter syndrome, type 3 9.7 TRPM6 SLC12A1 KCNJ1 CLDN19 CLDN16
33 gitelman syndrome 9.7 TRPM6 SLC12A1 KCNJ1 FXYD2 CLDN16
34 nephrolithiasis 9.6 SLC12A1 PTH KCNJ1 CLDN19 CLDN16
35 nephrocalcinosis 9.5 TRPM6 SLC12A1 PTH KCNJ1 CLDN19 CLDN16
36 bartter disease 9.3 TRPM6 TALDO1 SLC12A1 KCNJ1 CLDN19 CLDN16

Graphical network of the top 20 diseases related to Primary Hypomagnesemia:



Diseases related to Primary Hypomagnesemia

Symptoms & Phenotypes for Primary Hypomagnesemia

UMLS symptoms related to Primary Hypomagnesemia:


seizures, polydipsia, abdominal pain, polyuria, spasm

Drugs & Therapeutics for Primary Hypomagnesemia

Drugs for Primary Hypomagnesemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium Sulfate Approved, Investigational, Vet_approved 7487-88-9 24083
2 Anesthetics
3 Hormones
4 Anti-Arrhythmia Agents
5 Analgesics
6 Anticonvulsants
7 Calcium, Dietary
8 Tocolytic Agents
9 calcium channel blockers
10
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients Terminated NCT01426165 Magnesium Sulfate

Search NIH Clinical Center for Primary Hypomagnesemia

Genetic Tests for Primary Hypomagnesemia

Genetic tests related to Primary Hypomagnesemia:

# Genetic test Affiliating Genes
1 Primary Hypomagnesemia 29 CLDN16

Anatomical Context for Primary Hypomagnesemia

MalaCards organs/tissues related to Primary Hypomagnesemia:

40
Testes, Brain

Publications for Primary Hypomagnesemia

Articles related to Primary Hypomagnesemia:

(show all 41)
# Title Authors PMID Year
1
In-Depth Bioinformatic Study of the CLDN16 Gene and Protein: Prediction of Subcellular Localization to Mitochondria. 61
31357502 2019
2
Reversible Dilated Cardiomyopathy Due to Combination of Vitamin D-Deficient Rickets and Primary Hypomagnesemia in an 11-Month-Old Infant. 61
31073467 2018
3
Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6. 61
26273099 2015
4
Primary familial hypomagnesemia syndrome: a new approach in treatment. 61
22876566 2012
5
A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. 61
19307729 2009
6
Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. 61
17671655 2007
7
Etiology of nephrocalcinosis in northern Indian children. 61
17285294 2007
8
[Primary hypomagnesemia]. 61
16817383 2006
9
Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. 61
16107578 2005
10
The gamma subunit of Na/K-ATPase: an exceptional, small transmembrane protein. 61
15970522 2005
11
Insights into the molecular nature of magnesium homeostasis. 61
15001450 2004
12
Dominant isolated renal magnesium loss is caused by misrouting of the Na+,K+-ATPase gamma-subunit. 61
12763862 2003
13
Primary hypomagnesemia in Thai infants: a case report with 7 years follow-up and review of literature. 61
12546321 2002
14
Primary hypomagnesemia with secondary hypocalcemia in an infant. 61
11910142 2002
15
[Magnesium metabolism in chronic primary hypomagnesemia] 61
14647662 2000
16
Primary hypomagnesemia caused by isolated magnesium malabsorption: atypical case in adult. 61
10337938 1999
17
Symptomatic hypomagnesemia in children. 61
9926514 1998
18
[Primary hypomagnesemia]. 61
9645155 1998
19
Familial primary hypomagnesemia complicated with brain atrophy and cardiomyopathy. 61
9297931 1997
20
Primary idiopathic hypomagnesemia in two female siblings. 61
8652964 1995
21
Magnesium metabolism in childhood. 61
8264518 1993
22
Primary hypomagnesemia with a probable double magnesium transport defect. 61
2352584 1990
23
Primary hypomagnesemia with a probable double magnesium transport defect. 61
2710272 1989
24
Effect of serum magnesium concentration on renal handling of phosphate in a patient with primary hypomagnesemia. 61
3396512 1988
25
Primary hypomagnesemia with secondary hypocalcemia. Report of a case and review of the world literature. 61
2995735 1985
26
[Case of primary hypomagnesemia with functional hypoparathyroidism]. 61
4072167 1985
27
Parathyroid hormone secretion and responsiveness to parathyroid hormone in primary hypomagnesemia. 61
6853131 1983
28
[Primary hypomagnesemia with hypocalcemia. A cause of disease in a child]. 61
7163892 1982
29
[Primary hypomagnesemia. A rare cause of hypocalcemia and convulsions in infancy]. 61
7303277 1981
30
[A case of neonatal convulsions caused by transitory normocalcemic primary hypomagnesemia. Clinical considerations]. 61
7343929 1981
31
[Primary hypomagnesemia. Clinical, diagnostic and therapeutic studies in three children (author's transl)]. 61
759840 1979
32
[Editorial: Primary hypomagnesemia]. 61
1278784 1976
33
[Study of the pathogenic mechanism of hypocalcemia in primary hypomagnesemia. Demonstration of a blockage of the mechanism of release of parathyroid hormone]. 61
1217953 1975
34
[Syndrome of primary hypomagnesemia with secondary hypocalcemia. Report of a case]. 61
1223632 1975
35
Primary hypomagnesemia. I. Absorption Studies. 61
1130118 1975
36
Pathogenesis of hypocalcemia in primary hypomagnesemia: normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. 61
4345201 1973
37
Distribution of divalent cations at the cellular level during primary hypomagnesemia in infancy. 61
5053136 1972
38
Primary hypomagnesemia with secondary hypocalcemia, diarrhea and insensitivity to parathyroid hormone. 61
5032685 1972
39
[Congenital primary hypomagnesemia as a cause of spastic states in 2 infants]. 61
5095992 1971
40
Primary hypomagnesemia with secondary hypocalcemia in an infant. 61
5637791 1968
41
Congenital primary hypomagnesemia, an inborn error of metabolism? 61
5586087 1967

Variations for Primary Hypomagnesemia

ClinVar genetic disease variations for Primary Hypomagnesemia:

6 (show top 50) (show all 96) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CLDN16 NM_006580.3(CLDN16):c.678del (p.Gly227fs)deletion Pathogenic 438693 rs1553809654 3:190126187-190126187 3:190408398-190408398
2 CLDN16 NM_006580.3(CLDN16):c.416C>T (p.Ala139Val)SNV Pathogenic 545702 rs765256758 3:190120217-190120217 3:190402428-190402428
3 CLDN16 NM_006580.3(CLDN16):c.545_548dup (p.Lys183delinsAsnTer)duplication Pathogenic 545703 rs1253995767 3:190122666-190122667 3:190404877-190404878
4 CLDN16 NM_006580.3(CLDN16):c.602G>A (p.Gly201Glu)SNV Pathogenic 560390 rs138308105 3:190126112-190126112 3:190408323-190408323
5 CLDN16 NM_006580.3(CLDN16):c.698G>A (p.Gly233Asp)SNV Pathogenic 5932 rs104893727 3:190126208-190126208 3:190408419-190408419
6 CLDN16 NM_006580.3(CLDN16):c.704C>T (p.Ser235Phe)SNV Pathogenic 5933 rs104893728 3:190126214-190126214 3:190408425-190408425
7 CLDN16 NM_006580.3(CLDN16):c.453G>T (p.Leu151Phe)SNV Pathogenic 5934 rs104893729 3:190122576-190122576 3:190404787-190404787
8 CLDN16 NM_006580.3(CLDN16):c.452T>G (p.Leu151Trp)SNV Pathogenic 5935 rs104893730 3:190122575-190122575 3:190404786-190404786
9 CLDN16 NM_006580.3(CLDN16):c.434T>C (p.Leu145Pro)SNV Pathogenic 5936 rs104893731 3:190122557-190122557 3:190404768-190404768
10 CLDN16 NM_006580.3(CLDN16):c.350G>A (p.Trp117Ter)SNV Pathogenic 5937 rs104893732 3:190120151-190120151 3:190402362-190402362
11 CLDN16 CLDN16, LEU151PROundetermined variant Pathogenic 5938
12 CLDN16 NM_006580.3(CLDN16):c.831T>G (p.Tyr277Ter)SNV Pathogenic 5940 rs121908543 3:190127738-190127738 3:190409949-190409949
13 CLDN16 NM_006580.3(CLDN16):c.823A>T (p.Lys275Ter)SNV Pathogenic 30405 rs387906880 3:190127730-190127730 3:190409941-190409941
14 CLDN16 NM_006580.3(CLDN16):c.445C>T (p.Arg149Ter)SNV Pathogenic 5925 rs104893720 3:190122568-190122568 3:190404779-190404779
15 CLDN16 NM_006580.3(CLDN16):c.715G>A (p.Gly239Arg)SNV Pathogenic 5926 rs104893721 3:190126225-190126225 3:190408436-190408436
16 CLDN16 NM_006580.3(CLDN16):c.571G>A (p.Gly191Arg)SNV Pathogenic 5927 rs104893722 3:190122694-190122694 3:190404905-190404905
17 CLDN16 NM_006580.3(CLDN16):c.593G>A (p.Gly198Asp)SNV Pathogenic 5928 rs104893723 3:190126103-190126103 3:190408314-190408314
18 CLDN16 NM_006580.3(CLDN16):c.212T>G (p.Met71Arg)SNV Pathogenic 5929 rs104893724 3:190106120-190106120 3:190388331-190388331
19 CLDN16 NM_006580.3(CLDN16):c.500T>C (p.Leu167Pro)SNV Pathogenic 5930 rs104893725 3:190122623-190122623 3:190404834-190404834
20 CLDN16 NM_006580.3(CLDN16):c.695T>G (p.Phe232Cys)SNV Pathogenic/Likely pathogenic 5931 rs104893726 3:190126205-190126205 3:190408416-190408416
21 TRPM6 deletion Likely pathogenic 438256 9:77388717-77398576 9:74773801-74783660
22 CLDN16 NM_006580.3(CLDN16):c.427+5G>ASNV Likely pathogenic 692157 rs751959430 3:190120233-190120233 3:190402444-190402444
23 CLDN16 NM_006580.3(CLDN16):c.592G>C (p.Gly198Arg)SNV Likely pathogenic 802037 3:190122715-190122715 3:190404926-190404926
24 CLDN16 NM_006580.3(CLDN16):c.327G>A (p.Val109=)SNV Conflicting interpretations of pathogenicity 344449 rs528344809 3:190120128-190120128 3:190402339-190402339
25 CLDN16 NM_006580.3(CLDN16):c.227A>C (p.Gln76Pro)SNV Uncertain significance 344446 rs867514971 3:190106135-190106135 3:190388346-190388346
26 CLDN16 NM_006580.3(CLDN16):c.324+13C>GSNV Uncertain significance 344448 rs369250510 3:190106245-190106245 3:190388456-190388456
27 CLDN16 NM_006580.3(CLDN16):c.*1377T>ASNV Uncertain significance 344469 rs886058252 3:190129202-190129202 3:190411413-190411413
28 CLDN16 NM_006580.3(CLDN16):c.*1559C>ASNV Uncertain significance 344472 rs886058253 3:190129384-190129384 3:190411595-190411595
29 CLDN16 NM_006580.3(CLDN16):c.*724A>CSNV Uncertain significance 344456 rs886058247 3:190128549-190128549 3:190410760-190410760
30 CLDN16 NM_006580.3(CLDN16):c.*965G>ASNV Uncertain significance 344462 rs769075597 3:190128790-190128790 3:190411001-190411001
31 CLDN16 NM_006580.3(CLDN16):c.*1170G>ASNV Uncertain significance 344464 rs886058250 3:190128995-190128995 3:190411206-190411206
32 CLDN16 NM_006580.3(CLDN16):c.*1348A>GSNV Uncertain significance 344468 rs753612393 3:190129173-190129173 3:190411384-190411384
33 CLDN16 NM_006580.3(CLDN16):c.*1491A>GSNV Uncertain significance 344471 rs113286536 3:190129316-190129316 3:190411527-190411527
34 CLDN16 NM_006580.3(CLDN16):c.*1733A>GSNV Uncertain significance 344473 rs886058254 3:190129558-190129558 3:190411769-190411769
35 CLDN16 NM_001378492.1(CLDN16):c.-93-323G>TSNV Uncertain significance 900562 3:190105703-190105703 3:190387914-190387914
36 CLDN16 NM_001378492.1(CLDN16):c.-93-272C>TSNV Uncertain significance 902248 3:190105754-190105754 3:190387965-190387965
37 CLDN10 NM_006984.5(CLDN10):c.431C>T (p.Thr144Met)SNV Uncertain significance 694635 13:96212684-96212684 13:95560430-95560430
38 CLDN16 NM_006580.4(CLDN16):c.*1427A>GSNV Uncertain significance 899569 3:190129252-190129252 3:190411463-190411463
39 CLDN16 NM_006580.4(CLDN16):c.*1552T>GSNV Uncertain significance 900709 3:190129377-190129377 3:190411588-190411588
40 CLDN16 NM_006580.4(CLDN16):c.*1793G>CSNV Uncertain significance 900710 3:190129618-190129618 3:190411829-190411829
41 CLDN16 NM_006580.4(CLDN16):c.*1817T>CSNV Uncertain significance 902388 3:190129642-190129642 3:190411853-190411853
42 CLDN16 NM_006580.4(CLDN16):c.*1872C>ASNV Uncertain significance 902390 3:190129697-190129697 3:190411908-190411908
43 CLDN16 NM_006580.4(CLDN16):c.*1883T>GSNV Uncertain significance 902391 3:190129708-190129708 3:190411919-190411919
44 CLDN16 NM_006580.4(CLDN16):c.-132G>ASNV Uncertain significance 902250 3:190105987-190105987 3:190388198-190388198
45 CLDN16 NM_006580.4(CLDN16):c.-116G>TSNV Uncertain significance 902251 3:190106003-190106003 3:190388214-190388214
46 CLDN16 NM_006580.4(CLDN16):c.22A>G (p.Ile8Val)SNV Uncertain significance 903126 3:190106140-190106140 3:190388351-190388351
47 CLDN16 NM_006580.4(CLDN16):c.99T>C (p.Ala33=)SNV Uncertain significance 903127 3:190106217-190106217 3:190388428-190388428
48 CLDN16 NM_006580.4(CLDN16):c.192C>T (p.Tyr64=)SNV Uncertain significance 899500 3:190120203-190120203 3:190402414-190402414
49 CLDN16 NM_006580.4(CLDN16):c.539G>C (p.Gly180Ala)SNV Uncertain significance 899501 3:190126259-190126259 3:190408470-190408470
50 CLDN16 NM_006580.4(CLDN16):c.564T>C (p.Tyr188=)SNV Uncertain significance 899502 3:190126284-190126284 3:190408495-190408495

Expression for Primary Hypomagnesemia

Search GEO for disease gene expression data for Primary Hypomagnesemia.

Pathways for Primary Hypomagnesemia

Pathways related to Primary Hypomagnesemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 TRPM7 TRPM6 SLC8A1 SLC12A1 FXYD7 FXYD2
2
Show member pathways
12.05 TRPM7 TRPM6 FXYD7 FXYD2
3 11.06 SLC8A1 PTH FXYD2
4 10.97 KCNJ1 FXYD2
5 10.77 TRPM7 TRPM6
6 10.69 TRPM7 TRPM6 SLC8A1 FXYD2
7 10.59 SLC12A1 KCNJ1 FXYD2

GO Terms for Primary Hypomagnesemia

Cellular components related to Primary Hypomagnesemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 TRPM7 TRPM6 SLC8A1 SLC12A1 KCNJ1 HSPA1L

Biological processes related to Primary Hypomagnesemia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 calcium ion transport GO:0006816 9.73 TRPM7 TRPM6 SLC8A1
2 potassium ion transport GO:0006813 9.72 SLC12A1 KCNJ1 FXYD2
3 calcium ion transmembrane transport GO:0070588 9.67 TRPM7 TRPM6 SLC8A1
4 sodium ion transport GO:0006814 9.65 SLC8A1 SLC12A1 FXYD2
5 transmembrane transport GO:0055085 9.63 TRPM7 TRPM6 SLC8A1 SLC12A1 FXYD2 CNNM2
6 positive regulation of bone mineralization GO:0030501 9.58 SLC8A1 PTH
7 excretion GO:0007588 9.58 KCNJ1 CLDN16
8 calcium ion homeostasis GO:0055074 9.57 SLC8A1 PTH
9 protein tetramerization GO:0051262 9.54 TRPM7 TRPM6
10 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.52 CLDN19 CLDN16
11 regulation of sodium ion transmembrane transporter activity GO:2000649 9.51 FXYD7 FXYD2
12 regulation of cardiac conduction GO:1903779 9.5 SLC8A1 FXYD7 FXYD2
13 magnesium ion transmembrane transport GO:1903830 9.46 CNNM2 CLDN16
14 sodium ion export across plasma membrane GO:0036376 9.43 SLC8A1 FXYD2
15 potassium ion import across plasma membrane GO:1990573 9.43 SLC12A1 KCNJ1 FXYD2
16 ion transmembrane transport GO:0034220 9.43 TRPM7 TRPM6 SLC12A1 KCNJ1 FXYD7 FXYD2
17 regulation of ion transport GO:0043269 9.4 FXYD7 FXYD2
18 magnesium ion homeostasis GO:0010960 9.37 PTH CNNM2
19 ion transport GO:0006811 9.28 TRPM7 TRPM6 SLC8A1 SLC12A1 KCNJ1 FXYD7

Molecular functions related to Primary Hypomagnesemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium channel regulator activity GO:0017080 9.16 FXYD7 FXYD2
2 magnesium ion transmembrane transporter activity GO:0015095 8.96 CNNM2 CLDN16
3 ion channel regulator activity GO:0099106 8.62 FXYD7 FXYD2

Sources for Primary Hypomagnesemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....